China NMPA Drug Inspection - Anhui Jiren Pharmaceutical Co., Ltd. - Bone Spur Pain Relief Capsules

The National Medical Products Administration (NMPA), formerly the State Food and Drug Administration (SFDA), issued Announcement No. 105 of 2017 on July 13, 2017, detailing findings from drug testing institutions, including the Shanghai Municipal Institute for Food and Drug Control. This announcement reported that five batches of drugs from three companies were found to be substandard. The implicated companies are Chongqing Grelin Pharmaceutical Co., Ltd., Jiangxi Yuandong Pharmaceutical Co., Ltd., and Anhui Jiren Pharmaceutical Co., Ltd. Specific issues included problems with appearance, content determination, and identification for products like Pancreatic Enzyme Enteric-coated Tablets, Concentrated Vitamin B1 Phosphate Syrup, and Bone Spur Relief Capsules. In response, provincial food and drug administrations implemented immediate control measures, including sealing and seizing the affected products, mandating sales suspensions, recalls, and rectifications by the manufacturers. Furthermore, the SFDA required these provincial authorities to initiate investigations into the companies' illegal activities of producing and selling substandard drugs, in accordance with Articles 73, 74, and 75 of the *Drug Administration Law of the People's Republic of China*. The SFDA also stipulated that the outcomes of these actions must be publicly disclosed within three months and promptly reported to the administration.